Asthma affects more than 300 million people worldwide, and is the most common noncommunicable disease among children. No cure exists for chronic asthma; most patients rely on inhaled or systemic ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Current treatments focus on eosinophilic asthma, neglecting non-eosinophilic types. Developments in biologic therapies for severe asthma, challenges remain in managing T-helper cell type 2 (T2)-low ...

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...

Medically reviewed by Qin Rao, MD Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

This page compiles essential information on generic and brand-name drugs specifically used for Eosinophilic Esophagitis (EoE) treatment.Here, you can explore dosages, prices, side effects ...

LONDON: AstraZeneca's Fasenra, an injectable treatment ... breathing disorder called eosinophilic asthma that targets a type of white blood cell associated with lung inflammation.

The study highlights T2-low and T17-high asthma endotypes in minoritized youths, offering insights for precision medicine and improved asthma management.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

“While we are investigating recurrent, treatment refractory ... speculated that the presence of eosinophilic inflammation in the airway would predict asthma development.